. 2020 Apr 10;27(8):1975–1984. doi: 10.1016/j.sjbs.2020.04.004

Table 2.

Comparison of AUC for PSA derivatives and uPA as predictors for prostate cancer vs benign prostatic hyperplasia and vs healthy control men.

Parameter	PCa vs healthy control				PCa vs BPH
	AUC	Asymptotic Significant	Asymptotic 95% Confidence Interval		AUC	Asymptotic Significant	Asymptotic 95% Confidence Interval
	AUC	Asymptotic Significant	Lower	Upper	AUC	Asymptotic Significant	Lower	Upper
UPA	0.843	0.000*	0.757	0.930	0.779	0.000*	0.701	0.856
PSA	0.513	0.809	0.410	0.616	0.514	0.782	0.417	0.610
fPSA	0.202	0.000*	0.119	0.285	0.462	0.435	0.364	0.559
%fPSA	0.204	0.000*	0.123	0.286	0.432	0.164	0.336	0.528
P2PSA	0.724	0.000*	0.631	0.817	0.733	0.000*	0.644	0.822
%P2PSA	0.649	0.004*	0.552	0.746	0.594	0.055	0.499	0.689
PHI	0.887	0.000*	0.825	0.948	0.639	0.004*	0.546	0.733

. PHI: Prostate Health Index; PSA: prostate specific antigen; tPSA: total PSA; fPSA: free PSA; %fPSAZpercentage of free to total PSA; p2PSA: [-2]pro PSA; %p2PSA: percentage of p2PSA to fPSA ratio.